Integral BioSystems will have a booth at Table #41 on September 24, 2026, at the Hyatt Regency Hotel in New Brunswick, NJ
“No matter what your active ingredient is, we can assist you in formulating it to achieve maximum safety and efficacy in the final drug product.”— Shikha Barman, CEOBEDFORD, MA, UNITED STATES, September 8, 2026 /EINPresswire.com/ — Operating out of a 10,000‑square‑foot facility in Bedford, MA, the scientists at Integral BioSystems specialize in formulation and analytical method development, stability assessments, bioanalytics, and scale‑up/technology transfer.
Our team possesses extensive experience with Biodegradable Microspheres/Nanospheres, Drug Suspensions, Generics, 505B1, OTC and 505B2 Products, Small Molecules, Proteins (Biosimilars), and Nucleic acid formulations (DNA, RNAi), as well as Vaccines. Available delivery routes include Injectables, Ophthalmics, Intranasals, Otic, Pulmonary, and Dermal. Our development capabilities encompass R&D and cGLP; R&D and cGLP stability studies, toxicology supplies, process development, scale‑up, and technology transfer.
With more than 28 years of expertise spanning all stages of cell‑ and tissue‑targeted, sustained‑release pharmaceutical formulation development, the company’s CEO and President, Dr. Shikha P. Barman, will be present to discuss the unique needs of attendees.
About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that provides an integrated, hands‑on approach to formulation development projects for both small‑molecule and large‑molecule drug candidates. The firm offers contract services to pharmaceutical companies—helping them develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale‑up, and technology transfer—and also partners with pharmaceutical companies to co‑develop products based on its proprietary pharmaceutical delivery systems.
The Company has created numerous dosage forms for ophthalmic applications. Integral BioSystems employs a translational approach to drug development, tailoring delivery systems to meet the biologically effective goals of the therapy. Dosage forms are customized to provide sustained release, targeted tissue‑focused delivery, or fast‑release/instant delivery, depending on the desired product characteristics.
For those interested in developing a formulation for a new drug substance, a 505b2 product, or a generic drug product, Dr. Barman will be available to answer questions about possible strategies for your specific application.
Dave Karasic
Integral BioSystems, LLC
+ +1 617-820-8483
email us here
